These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 18382330)

  • 1. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.
    Ogden AT; Waziri AE; Lochhead RA; Fusco D; Lopez K; Ellis JA; Kang J; Assanah M; McKhann GM; Sisti MB; McCormick PC; Canoll P; Bruce JN
    Neurosurgery; 2008 Feb; 62(2):505-14; discussion 514-5. PubMed ID: 18382330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limits of CD133 as a marker of glioma self-renewing cells.
    Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I
    Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma.
    Rebetz J; Tian D; Persson A; Widegren B; Salford LG; Englund E; Gisselsson D; Fan X
    PLoS One; 2008 Apr; 3(4):e1936. PubMed ID: 18398462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.
    Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A
    Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A2B5 cells from human glioblastoma have cancer stem cell properties.
    Tchoghandjian A; Baeza N; Colin C; Cayre M; Metellus P; Beclin C; Ouafik L; Figarella-Branger D
    Brain Pathol; 2010 Jan; 20(1):211-21. PubMed ID: 19243384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cancer stem cells through L1CAM suppresses glioma growth.
    Bao S; Wu Q; Li Z; Sathornsumetee S; Wang H; McLendon RE; Hjelmeland AB; Rich JN
    Cancer Res; 2008 Aug; 68(15):6043-8. PubMed ID: 18676824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors.
    Beier D; Wischhusen J; Dietmaier W; Hau P; Proescholdt M; Brawanski A; Bogdahn U; Beier CP
    Brain Pathol; 2008 Jul; 18(3):370-7. PubMed ID: 18371181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the clinical value of cancer stem cell markers in gliomas?
    Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW
    Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
    Song WC; Fei XF; Dong J
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A distinct subpopulation within CD133 positive brain tumor cells shares characteristics with endothelial progenitor cells.
    Choi SA; Wang KC; Phi JH; Lee JY; Park CK; Park SH; Kim SK
    Cancer Lett; 2012 Nov; 324(2):221-30. PubMed ID: 22652175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays.
    He J; Liu Y; Zhu T; Zhu J; Dimeco F; Vescovi AL; Heth JA; Muraszko KM; Fan X; Lubman DM
    Mol Cell Proteomics; 2012 Jun; 11(6):M111.010744. PubMed ID: 22203689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study on the proliferation and drug-resistance of human brain tumor stem-like cells.
    Qin K; Jiang X; Zou Y; Wang J; Qin L; Zeng Y
    Cell Mol Neurobiol; 2010 Aug; 30(6):955-60. PubMed ID: 20526804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma.
    Hua W; Yao Y; Chu Y; Zhong P; Sheng X; Xiao B; Wu J; Yang B; Mao Y; Zhou L
    J Neurooncol; 2011 Nov; 105(2):149-57. PubMed ID: 21479962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.
    Wang J; Sakariassen PØ; Tsinkalovsky O; Immervoll H; Bøe SO; Svendsen A; Prestegarden L; Røsland G; Thorsen F; Stuhr L; Molven A; Bjerkvig R; Enger PØ
    Int J Cancer; 2008 Feb; 122(4):761-8. PubMed ID: 17955491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
    Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R
    Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How powerful is CD133 as a cancer stem cell marker in brain tumors?
    Cheng JX; Liu BL; Zhang X
    Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
    Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
    J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
    Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G
    Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
    Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
    Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.